摘要:
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.
摘要:
The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]
摘要:
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.
摘要翻译:本发明涉及由下式表示的化合物,其药理学上可接受的盐或其作为药物的用途:其中R 1和R 2是相邻的取代基 并且与它们各自连接的两个碳原子一起形成5-至7-元非芳族碳环基等,其可以被1至4个选自以下的取代基取代:(1)氧代 基团,(2)羟基等; R 3表示氢原子等; R 6表示氢原子等。 本发明的目的是发现用于治疗或预防下尿路症状的药剂,特别是关于尿液储存的症状,其具有优于5-HT 1A受体的结合强度和对受体的拮抗作用。
摘要:
The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.
摘要翻译:本发明涉及由下式表示的化合物,其药理学上可接受的盐或其作为药物的用途:其中R 1和R 2是相邻的取代基 并且与它们各自连接的两个碳原子一起形成5-至7-元非芳族碳环基等,其可以被1至4个选自以下的取代基取代:(1)氧代 基团,(2)羟基等; R 3表示氢原子等; R 6表示氢原子等。 该化合物与5-HT 1A受体的结合强度优异,对受体具有拮抗作用,可用作治疗或预防下尿路症状的药剂,特别是有关尿液储存的症状。
摘要:
The invention provides an N,N-substituted cyclic amine compound represented by the following formula (VIII): wherein A represents an aryl group etc.; E represents a group represented by the formula —CO— or a group represented by the formula —CHOH—; G represents an oxygen atom etc.; J represents an aryl group which may be substituted; R1 represents a lower alkyl group etc.; Alk represents a linear or branched lower alkylene group; n, v, w, x and y are independent of each other and each represents 0 or 1; and p represents 2 or 3, or a pharmacologically acceptable salt thereof. The compound of the present invention or a salt thereof is effective to treat a disease against which calcium antagonism is effective. The disease may include acute ischemic stroke, cerebral apoplexy, cerebral infarction, head trauma, cerebral nerve cell death, Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, Huntington disease, cerebral circulatory metabolism disturbance, cerebral function disturbance, pain, spasm, schizophrenia, migraine, epilepsy, maniac-depressive psychosis, nerve degenerative diseases, cerebral ischemia, AIDS dementia complications, edema, anxiety disorder (generalized anxiety disorder) and diabetic neuropathy.
摘要:
A crystal of 1-[1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)-ethyl]piperidin-4-yl]-N-methyl-1H-indole-6-carboxamide fumarate which has peaks at chemical shifts of about 124.0 ppm and about 26.8 ppm in a 13C solid NMR spectrum.
摘要:
The present invention provides a novel nitrile compound useful as an intermediate for the production of, for example, N,N-substituted cyclic amine derivatives or phenylacetonitrile derivatives that are useful as a medicine. Specifically it provides a nitrile carboxylic acid compound, nitrile ester compound and nitrile alcohol compound. That is, it provides a nitrile compound represented by the following formula (I): wherein R1 and R2 means substituents; m means 0 or an integer of from 1 to 6; n means 0 or an integer of from 1 to 5; and R3 means carboxyl group, a lower alkoxycarbonyl group or hydroxymethyl group.
摘要翻译:本发明提供了可用作制备例如可用作药物的N,N-取代的环胺衍生物或苯乙腈衍生物的中间体的新型腈化合物。 具体地说,它提供了一种腈羧酸化合物,腈酯化合物和腈醇化合物。 也就是说,它提供由下式(I)表示的腈化合物:其中R 1和R 2表示取代基; m表示0或1〜6的整数; n表示0或1至5的整数; R 3表示羧基,低级烷氧基羰基或羟甲基。
摘要:
A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
摘要:
In a mobile terminal provided with an encoded data recording function, there is assumed a condition in which a picture frame transmitted from the terminal of a communication partner is reproduced by means of decoding processing and is displayed on a LCD (34) during wireless TV phone communication. In this condition, when a user carries out a picture recording start operation, display picture data reproduced by means of decoding processing in the multimedia processing section (24) to be displayed on the LCD (34) are recorded in a main recording section (26).
摘要:
A main body controller provided in an image forming apparatus receives a VDP job from an external computer, and arranges image data of a reusable object and a variable object, which correspond to the VDP job, on a page for printout. An inspection controller performs inspection processing for printed matter for each page, and the main body controller preferentially stores image data of the reusable object, which corresponds to the page for which the printing has been determined to be defective as a result of inspection processing, in a cache unit. The main body controller acquires the reusable object, which corresponds to the page for which the printing has been determined to be defective, from the cache unit, and executes page reprint processing using the acquired reusable object.